TP53 codon 72 Polymorphism and P53 Protein Expression in Colorectal Cancer Specimens in Isfahan

  • Mehdi Nikbahkt Dastjerdi Department of Anatomy, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Keywords: Colorectal neoplasms, Adenocarcinoma, TP53, Arginine, Proline, Polymorphism


The TP53 tumor suppressor gene plays important roles in genomic stability. A common polymorphism at codon 72 of TP53 gene has been associated with increased risk for many human cancers. The p53 protein is expressed in colorectal cancer, but the reported prevalence of its expression varies widely. In the present study, the p53 protein expression in different genotypes of its codon 72 , was investigated. We undertook a case-control study on 250 controls and 250 paraffin block specimens of sporadic colorectal adenocarcinomas from the city of Isfahan. PCR amplification of TP53 codon 72 polymorphism: TP53 codon 72 genotypes were detected by PCR using specific primer pairs for amplifying the proline or the arginine Alleles. The PCR reaction was done separately for each of the two polymorphic variants. The amplified products were subjected to electrophoresis on 1% agarose gel in 1× TBE buffer and visualized on a transilluminator using ethidium bromide. Immunohistochemical Staining: We evaluated the expression patterns of p53 protein, as potential prognostic marker in colorectal cancer specimens by immunohistochemical staining. Statistical analyses: The χ2-test was used to assess the significance of any difference in the prevalence of TP53 codon 72 polymorphism between colorectal cancer patients and controls. The odds ratio and 95% CI (confidence intervals) was used as a measure of the strength of the association. Statistical significance level was set to P≤0.05. In control samples, the genotype distribution for TP53 polymorphism showed 30.4%, 45.2% and 24.4% for the arginine/arginine, arginine/proline and proline/proline genotypes, respectively. Allelic frequencies corresponded to 0.663 for the arginine allele and 0.338 for the proline allele. In the cancer group 38.8% of the cases were arginine/arginine, 40.4% were arginine/proline and 20.8% were proline/proline. The corresponding frequencies were 0.590 for the arginine allele and 0.410 for the proline allele. A significant difference between cases and controls was found for the arginine/arginine genotype compared with (grouped) arginine/proline and proline/proline genotypes (Odds Ratio = 1.451 (1.002-2.103), P=0.048). Overexpression of p53 was observed in 50.8 percent of cancer specimens which most of them were arginine/arginine genotype (P


Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002;137(7):603-12.

Gazelle GS, McMahon PM, Scholz FJ. Screening for colorectal cancer. Radiology 2000;215(2):327-35.

Dulić V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76(6):1013-23.

Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;264(1):56-66.

Sherr CJ. Principles of tumor suppression. Cell 2004;116(2):235-46.

Kaelin WG Jr. The p53 gene family. Oncogene 1999;18(53):7701-5.

Robles AI, Harris CC. p53-mediated apoptosis and genomic instability diseases. Acta Oncol 2001;40(6):696-701.

Prives C, Hall PA. The p53 pathway. J Pathol 1999;187(1):112-26.

Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor- Robinson SD. p53 Mutations in human cholangiocarcinoma: a review. Liver Int 2005;25(4):704-16.

Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21(3):292-300.

Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19(6):607-14.

Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1(3):233-40.

Sreeja L, Syamala V, Raveendran PB, Santhi S, Madhavan J, Ankathil R. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 2008;26(1):41-6.

Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996;1287(2-3):77-102.

Yamagiwa H, Onishi N, Onishi T, Onishi T, Onishi H, Watanabe K, Kadowaki Y, Nishii M, Kato Y.Immunohistochemical study of PCNA, EGFR, c-erbB-2 and p53 in carcinomas of large intestine. Rinsho Byori 1995;43(7):703-7.

Saleh HA, Jackson H, Banerjee M. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 2000;8(3):175-82.

Zhang Hong. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma. Clin Cancer Res 1999;5(12):4126-32.

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19(2):1092-100.

Dumont P, Leu JI, Della Pietra AC 3rd, George DL,Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33(3):357-65.

Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, WienckeJK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9(10):1037-42.

Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, Chen CJ, Hsieh CY, Wu MT. Genetic polymorphisms of p53 and GSTP1,but not NAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000;89(5):458-64.

Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with= cervical cancer. Lancet 1999;354(9174):218-9.

Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association withbladder cancer. Cancer Lett 2002;179(2):175-83.

Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005;222(1):57-65.

Langerod A, Bukholm IR, Bregard A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11(12):1684-8.

Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004;25(11):1568-73.

Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183(2):123-30.

Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003;82(2):111-20.

Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, Tsai CH. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 2002;112(1):116-9.

Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999;29(3):697-702.

Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12(9):1426-9.

Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004;130(12):728-32. Epub 2004 Sep 7.

Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23(10):1954-6.

Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007;37(5):385-90.

Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14(6):1085-9.

Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996;17(2):261-4.

Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K. No associations of p73 G4C14-to- A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181(1):81-5.

Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association withhuman papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109(1-2):25-34.

Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 prolinemp53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004;6(5):529-35.

Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ,Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991;86(4):369-70.

Själander A, Birgander R, Athlin L, Stenling R, Rutegård J, Beckman L, Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer.Carcinogenesis 1995;16(7):1461-4.

Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD,Fuchs CS, Giovannucci EL, Hunter DJ. p53 Arg72Propolymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006;119(8):1863-8.

Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, BanksL. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393(6682):229-34.

Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa Sh, Hinds PhW W, Tim Crook T, Kaelin Jr WG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25(1):47-54.

Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst 1999;91(7):594-8.

Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 2003;22(34):5252-60.

Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14(7):1026-38.

How to Cite
Nikbahkt Dastjerdi M. TP53 codon 72 Polymorphism and P53 Protein Expression in Colorectal Cancer Specimens in Isfahan. Acta Med Iran. 49(2):71-77.